Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Passes Above 200-Day Moving Average – Should You Sell?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.13 and traded as high as $15.48. Enanta Pharmaceuticals shares last traded at $13.74, with a volume of 240,513 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts recently commented on ENTA shares. JPMorgan Chase & Co. started coverage on Enanta Pharmaceuticals in a report on Friday, November 14th. They set an “overweight” rating and a $17.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Trading Down 10.8%

The business has a 50-day moving average of $13.85 and a two-hundred day moving average of $12.13. The firm has a market cap of $398.73 million, a P/E ratio of -4.29 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The business had revenue of $18.62 million during the quarter, compared to analyst estimates of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. As a group, equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ENTA. Seven Fleet Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $36,000. Virtu Financial LLC acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth approximately $220,000. Invesco Ltd. lifted its stake in shares of Enanta Pharmaceuticals by 325.2% in the fourth quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock worth $4,003,000 after acquiring an additional 194,113 shares during the period. Krensavage Asset Management LLC boosted its holdings in Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after acquiring an additional 651,946 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Enanta Pharmaceuticals during the 4th quarter valued at approximately $997,000. 94.99% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.